June 25, 2013 /PRNewswire/ --
Dynavax Technologies Corporation
Lifshitz Law Firm announces that a class action suit was filed in the United States District Court for the Northern District of
California, alleging that Dynavax Technologies Corporation ("Dynavax" or the "Company") (DVAX) issued false and misleading statements to investors between
April 26, 2012 and
June 10, 2013, inclusive (the "Class Period"). On
June 10, 2013, the Company disclosed that in a meeting with the FDA over its biologic license application for hepatitis-B vaccine Heplisav, the FDA expressed that it wanted additional safety data from more patients before approving the drug. The FDA further expressed that analyzing Heplisav for smaller groups of patients did not fully address its concerns and that it would like to see additional safety trials. Moreover, as previously noted by the FDA, the Company disclosed that there were ongoing concerns regarding Dynavax's manufacturing and testing of Heplisav.
For more information, please contact
Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to:
Keynote Systems, Inc.
Lifshitz Law Firm
announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Keynote Systems, Inc. ("Keynote") (KEYN) to an affiliate of
, LLC in an all-cash transaction valued at approximately
Lifshitz Law Firm's investigation is focused on whether the proposed deal provides adequate value to Keynote's shareholders.
For more information about our investigation, please contact
Joshua M. Lifshitz, Esq.
by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to:
Lifshitz Law Firm
announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of sTec, Inc. ("sTec") to Western Digital® Corporation in a transaction valued at approximately
in cash, which equates to
Lifshitz Law Firm's investigation is focused on whether the proposed deal provides adequate value to sTec's shareholders.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts